Fusion protein, mRNA delivery system based on fusion protein and application
By using a fusion protein of Listeriolysin O, GS linker, and L7Ae proteins with protamine, a novel mRNA delivery system was formed, solving the stability and cost issues of lipid nanoparticle delivery systems. This system enables efficient and low-cost mRNA delivery to target cells and is suitable for the preparation of mRNA transfection reagents and vaccines.
Patent Information
- Application Number
- CN202411055706.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-02
AI Technical Summary
Existing lipid nanoparticle delivery systems have shortcomings in terms of stability, cost, and preparation complexity, and traditional physical and viral vector methods have safety and effectiveness issues, making it difficult to effectively deliver mRNA to target cells.
A novel mRNA delivery system was developed by using a fusion protein, including Listeneriolysin O, GS linker, and L7Ae protein, combined with the cationic polymer protamine. This system delivers mRNA to target cells. Listeneriolysin O in the fusion protein plays an endosome escape role, while L7Ae protein plays a role in binding to mRNA.
This novel mRNA delivery system has fewer components, a simpler preparation process, lower cost, and greater stability. It can efficiently deliver mRNA to target cells and is suitable for the preparation of mRNA transfection reagents and vaccines, thus enabling its industrial application.
Smart Images

Figure CN118955735A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biological delivery, and in particular to a fusion protein and an mRNA delivery system and application based thereon. Background Art
[0002] mRNA needs to overcome the multiple challenges of the cell's "extracellular barrier" and the "endosome escape" and "intracellular immunity" before reaching the target site in the cell and finally exerting its function. Therefore, how to deliver mRNA into the cytoplasm of the target cell is a difficult problem that needs to be overcome for mRNA to exert its function.
[0003] Traditional methods of delivering mRNA vaccines include physical methods and viral vector methods. Electroporation and gene guns are classic methods of physical delivery of mRNA, but clinical trials have shown that physical methods are usually harmful to cells and are not suitable for in vivo application. The method of delivering mRNA based on viral vectors has many problems in terms of safety, stability, and effectiveness, so a more effective delivery system needs to be developed urgently.
[0004] Lipid nanoparticles (LNPs) have become a new mRNA delivery system that has attracted much attention in recent years due to their low immunogenicity, good biocompatibility and high mRNA encapsulation efficiency, and are now in clinical use.
[0005] Lipid nanoparticles (LNPs) have the following shortcomings: (1) Stability is a problem and they need to be stored at -20°C to -80°C. Moreover, LNPs in aqueous solution will change in size and lose their effectiveness. (2) The production cost is high and they require expensive microfluidic equipment for preparation. (3) The composition is relatively complex and requires four ingredients: ionizable lipids, cholesterol, distearoylphosphatidylcholine and PEG. Summary of the invention
[0006] The purpose of the present invention is to provide a novel fusion protein and a novel mRNA delivery system based on the fusion protein. Compared with conventional lipid nanoparticle delivery systems, the novel mRNA delivery system has fewer components, a simpler preparation process, lower cost and is more stable, and can be used as a transfection reagent and vaccine delivery system.
[0007] The technical solution of the present invention is as follows:
[0008] The first object of the present invention is to provide a fusion protein, which includes Listeriolysin O (LLO), GS linker and L7Ae protein, wherein the Listeriolysin O is connected to the N-terminus of the L7Ae protein through the GS linker.
[0009] Furthermore, the amino acid sequence of the fusion protein is as shown in SEQ ID NO.1:
[0010] SEQ ID NO.1:
[0011] MHHHHHHKDASAFNKENSISSMAPPASPPASPKTPIEKKHADEIDKYIQGLDYNKNNVLVY
[0012] HGDAVTNVPPRKGYKDGNEYIVVEKKKKSINQNNADIQVVNAISSLTYPGALVKANSELVE
[0013] NQPDVLPVKRDSLTLSIDLPGMTNQDNKIVVKNATKSNVNNAVNTLVERWNEKYAQAYPN
[0014] VSAKIDYDDEMAYSESQLIAKFGTAFKAVNNSLNVNFGAISEGKMQEEVISFKQIYYNVNV
[0015] NEPTRPSRFFGKAVTKEQLQALGVNAENPPAYISSVAYGRQVYLKLSTNSHSTKVKAAFDA
[0016] AVSGKSVSGDVELTNIIKNSSFKAVIYGGSAKDEVQIIDGNLGDLRDILKKGATFNRETPGVP
[0017] IAYTTNFLKDNELAVIKNNSEYIETTSKAYTDGKINIDHSGGYVAQFNISWDEVNYDPEGNEI
[0018] VQHKNWSENNKSKLAHFTSSIYLPGNARNINVYAKECTGLAWEWWRTVIDDRNLPLVKNR
[0019] NISIWGTTLYPKYSNKVDNPIEGGGGSGGGGSGGGGSMGRSMYVRFEVPEDMQNEALSLLE
[0020] KVRESGKVKKGTNETTKAVERGLAKLVYIAEDVDPPEIVAHLPLLCEEKNVPYIYVKSKNDLGRAVGIEVPCASAAIINEGELRKELGSLVEKIKGLQKGSA*
[0021] The second object of the present invention is to provide an mRNA delivery system based on the aforementioned fusion protein, the mRNA delivery system comprises a cationic polymer, the aforementioned fusion protein, and mRNA, wherein the cationic polymer encapsulates and protects the mRNA, the 3'UTR end of the mRNA binds to the C-terminus of the L7Ae protein in the fusion protein, and the Listeriolysin O in the fusion protein is connected to the N-terminus of the L7Ae protein. The Listeriolysin O plays an endosomal escape role, and L7Ae plays a role in binding to the mRNA.
[0022] Furthermore, in the mRNA delivery system, the molar ratio of the fusion protein to the mRNA is 0.125 to 1:1; the mass ratio of the mRNA to the cationic polymer is 6:1;
[0023] Preferably, in the mRNA delivery system, the molar ratio of the fusion protein to the mRNA is 1:1, 0.5:1, 0.25:1, 0.125:1;
[0024] Further preferably, in the mRNA delivery system, the molar ratio of the pre-fusion protein to the mRNA is 1:1.
[0025] Furthermore, the cationic polymer is protamine.
[0026] Furthermore, the mRNA is negatively charged, and the cationic polymer neutralizes the negatively charged mRNA and wraps and protects it.
[0027] Furthermore, the 3'UTR end of the mRNA is connected to a Box C / D sequence.
[0028] Preferably, the Box C / D sequence is shown in SEQ ID NO.2:
[0029] GGGCGUGAUGCGAAAGCUGACCCGGGCGUGAUGCGAAAGCUGACCCGCUCUGACCGA AAGGCGUGAUGAGCGCUCUGACCGAAAGGCGUGAUGAGC.
[0030] The Box C / D sequence shown in SEQ ID NO.2 is added to the 3'UTR end of the mRNA sequence by artificial synthesis. After having the Box C / D sequence, the mRNA can achieve binding with the Listeriolysin O+GS linker+L7Ae fusion protein.
[0031] In a specific embodiment, the mRNA is p30-mRNA.
[0032] Furthermore, the protamine encapsulates and protects the mRNA, the Box C / D sequence at the 3'UTR end of the mRNA binds to the L7Ae protein in the fusion protein, and the Listeriolysin O in the fusion protein is connected to the N-terminus of the L7Ae protein.
[0033] The third object of the present invention is to provide the use of the aforementioned fusion protein in preparing an mRNA delivery system.
[0034] The fourth object of the present invention is to provide the use of the aforementioned fusion protein or the aforementioned mRNA delivery system in the preparation of an mRNA transfection reagent or in the preparation of an mRNA drug or an mRNA vaccine.
[0035] The beneficial effects of the present invention are:
[0036] (1) The present invention provides a novel fusion protein with a clear amino acid sequence, which can be prepared in large quantities with high yield and controllable quality.
[0037] (2) The present invention also provides a new mRNA delivery system that can replace the liposome mRNA delivery system. Compared with the conventional lipid nanoparticle delivery system, the new mRNA delivery system has fewer components, a simpler preparation process, lower costs and is more stable. In addition, in the new mRNA delivery system, the mRNA is wrapped and protected by a cationic polymer (such as protamine, etc.), making it more stable.
[0038] (3) The novel fusion protein and novel mRNA delivery system can be used to prepare mRNA transfection reagents or prepare mRNA drugs or mRNA vaccines. The preparation process is simple, the cost is lower, and it is suitable for industrial application. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 :Schematic diagram of the new mRNA delivery system;
[0040] Figure 2 : Fluorescence image of protamine / Listeriolysin O+GS linker+L7Ae / eGFP-mRNA complex solution transfected into 293T cells for expression;
[0041] Figure 3 : Western blot after protamine / Listeriolysin O+GS linker+L7Ae / p30-mRNA complex solution was transfected into 293T cells for expression;
[0042] Figure 4 :The results of antibody detection in the serum of mice immunized with protamine / Listeriolysin O+GS linker+L7Ae / p30-mRNA complex. DETAILED DESCRIPTION
[0043] The present invention is further explained below with reference to the examples, but the examples do not limit the present invention in any form.
[0044] Example 1 Screening of the dosage ratio of Listeriolysin O+GS linker+L7Ae and mRNA
[0045] 1. Preparation of complexes of Listeriolysin O+GS linker+L7Ae and mRNA at different ratios
[0046] Listeriolysin O+GS linker+L7Ae and eGFP-mRNA containing Box C / D sequence were added to 50 μL PBS solution at a ratio of 1:1, 0.5:1, 0.25:1 and 0.125:1 (mol / mol), i.e., 1.30:3, 0.65:3, 0.32:3 and 0.16:3 (μg / μg), respectively, and then incubated to obtain solution A. 1 , A 2 , A 3 and A 4 , and then mixed with solution B (protamine solution, 18 μg protamine added to 50 μL PBS) and incubated to obtain protamine / Listeriolysin O+GS linker+
[0047] L7Ae / mRNA complex solution A 1 B. A 2 B. A 3 B and A 4 B.
[0048] 2. Transfection of 293T cells
[0049] Select 293T cells that can grow stably and plate them on a six-well plate. When the cells are 70-80% full, transfect them. Aspirate the culture medium in the culture dish and replace it with 1 mL of Opti-MEM culture medium. After the A and B mixtures are mixed and incubated, add the complex solution A 1 B. A 2B. A 3 B and A 4 B were added to 293T cells, replaced with complete medium after 6 h, and cultured for another 24 h.
[0050] 3. Observe and take photos under a fluorescence microscope
[0051] The above was added with complex solution A 1 B. A 2 B. A 3 B and A 4 The 293T cell 6-well plate of B was observed under a fluorescence microscope and photographed. The results are shown in Figure 2 Listeriolysin O+GS linker+L7Ae fusion protein and mRNA were able to complete delivery at the above four ratios, among which the mass ratio was 1.30:3, that is, the molar ratio was 1:1, and the delivery effect was the best, which was not worse than Lip2000:eGFP-mRNA (5μl:3μg).
[0052] Example 2 Preparation of protamine / Listeriolysin O+GS linker+L7Ae / p30-mRNA complex
[0053] 13 μg of Listeriolysin O+GS linker+L7Ae and 30 μg of p30-mRNA solution containing Box C / D sequence were added to 500 μL of PBS solution and incubated to obtain solution A. 180 μg of protamine was added to 500 μL of PBS solution and incubated to obtain solution B. Solution A and solution B were mixed and incubated to obtain protamine / Listeriolysin O+GS linker+
[0054] L7Ae / p30-mRNA complex ( Figure 1 ) solution.
[0055] Example 3 Protamine / Listeriolysin O+GS linker+L7Ae / p30-mRNA complex transfection of 293T cells 1. Transfection of 293T cells
[0056] 293T cells that can grow stably were plated on 6-well plates, and transfection was performed when the cells grew to 70-80%. The culture medium in the culture dish was discarded and replaced with 1 mL of Opti-MEM culture medium. The complex solution of protamine / Listeriolysin O+GS linker+L7Ae / p30-mRNA prepared in Example 2 (containing 3 μg p30-mRNA) was added to the 293T cells, mixed well, and placed in a CO 2Culture in an incubator at 37°C, replace with complete medium after 6 hours, and continue culture for 24 hours.
[0057] 2. Detection of ASFV p30 protein by immunoblotting
[0058] Total protein was extracted from transfected cells 48 hours after cell transfection and culture, and then polyacrylamide gel electrophoresis was performed after adding 6× loading buffer and boiling water bath for 5 minutes; the separated protein bands in the gel were transferred to cellulose acetate membrane by electrotransfer; blocked with 5% milk at room temperature for 60 minutes, washed 3 times with TBST; incubated with p30 antibody diluted 1000 times with 1% BSA-TBST solution at 4°C overnight, washed 3 times with TBST; added HRP-labeled mouse anti-rabbit IgG, incubated at room temperature for 120 minutes, washed 3 times with TBST; developed with enhanced chemiluminescence kit (ECL) and scanned and photographed. The results are shown in Figure 3 As shown, this delivery system can successfully deliver p30-mRNA into eukaryotic cells for expression.
[0059] Example 4 Immunization of mice with protamine / listeriolysin O+GS linker+L7Ae / p30-mRNA complex 1. Immunization of mice
[0060] Six female C57 mice weighing 18-20 g were selected; three mice in the immunization group were injected with protamine / Listeriolysin O+GS linker+L7Ae / p30-mRNA complex solution, and three mice in the blank group were injected with PBS solution. The PBS solution of protamine / Listeriolysin O+GS linker+L7Ae / p30-mRNA complex (i.e., the mRNA delivery system of the fusion protein of the present invention, with a p30-mRNA amount of 2 μg) was injected into the posterior thigh muscle of the mice in the immunization group, and 100 μl of PBS solution was injected into the blank group in the same manner; 14 days after the initial immunization, booster immunization was performed in the same manner and at the same dose.
[0061] 2. Detection of mouse-specific antibodies by immunoblotting
[0062] 14 days after booster immunization, blood was collected from the orbital vein of the mice, and the serum was separated and tested for specific antibodies using immunoblotting. The specific operation steps are as follows: After culturing the transfected 293T cells in Example 3 for 48 hours, the total protein of the transfected cells is extracted, and then 6× loading buffer is added and boiled in a boiling water bath for 5 minutes, and polyacrylamide gel electrophoresis is performed. The transfected 293T cells in Example 3 are loaded in parallel 6 times; gel electrotransfer to transfer the protein to the cellulose acetate membrane; block with 5% milk at room temperature for 60 minutes, and wash with TBST 3 times; cut the 25Kda~35Kda cellulose acetate membrane corresponding to each sample lane separately, and obtain 6 small membranes in total; the serum of 6 mice in the vaccine group and the blank group, each mouse serum is diluted 500 times with 1% BSA-TBST solution as the primary antibody, and the serum of 1 mouse corresponds to 1 small membrane, incubate at 4°C overnight, and wash 3 times with TBST; add HRP-labeled rabbit anti-mouse IgG, incubate at room temperature for 120 minutes, and wash 3 times with TBST; use enhanced chemiluminescence kit (ECL) to develop color and scan and take pictures. The results are as follows Figure 4 As shown, only mice immunized with protamine / Listeriolysin O+GSlinker+L7Ae / p30-mRNA complexes can produce specific antibodies.
[0063] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A fusion protein, characterized in that The fusion protein includes Listeriolysin O, GS linker and L7Ae protein, and the Listeriolysin O is connected to the N-terminus of the L7Ae protein through the GS linker.
2. The fusion protein according to claim 1, characterized in that The amino acid sequence of the fusion protein is shown in SEQ ID NO.
1.
3. An mRNA delivery system based on the fusion protein according to claim 1, characterized in that: The mRNA delivery system comprises a cationic polymer, the fusion protein according to claim 1, and mRNA. The cationic polymer wraps and protects the mRNA. The 3'UTR end of the mRNA is bound to the C-terminus of the L7Ae protein in the fusion protein. The Listeriolysin O in the fusion protein is connected to the N-terminus of the L7Ae protein.
4. The mRNA delivery system according to claim 3, characterized in that In the mRNA delivery system, the molar ratio of the fusion protein of claim 1 to the mRNA is 0.125 to 1:1; the mass ratio of the mRNA to the cationic polymer is 6:1; Preferably, in the mRNA delivery system, the molar ratio of the fusion protein to mRNA according to claim 1 is 1:1, 0.5:1, 0.25:1, or 0.125:1; Further preferably, in the mRNA delivery system, the molar ratio of the fusion protein according to claim 1 to mRNA is 1:
1.
5. The mRNA delivery system according to claim 3, characterized in that The cationic polymer is protamine.
6. The mRNA delivery system according to claim 3 or 4, characterized in that The mRNA is negatively charged.
7. The mRNA delivery system according to claim 5, characterized in that The 3'UTR end of the mRNA is connected to the Box C / D sequence; preferably, the Box C / D sequence is shown in SEQ ID NO.
2.
8. The mRNA delivery system according to claim 5, characterized in that The protamine wraps and protects the mRNA, the Box C / D sequence at the 3'UTR end of the mRNA binds to the C-terminus of the L7Ae protein in the fusion protein, and the Listeriolysin O in the fusion protein is connected to the N-terminus of the L7Ae protein.
9. Use of the fusion protein according to claim 1 or 2 in preparing an mRNA delivery system.
10. Use of the fusion protein according to claim 1 or 2 or the mRNA delivery system according to any one of claims 3 to 8 in the preparation of an mRNA transfection reagent or an mRNA drug or an mRNA vaccine.
Citation Information
Patent Citations
Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
CN107250366A
Bacterium expression vector for identifying tumor new antigens and method for screening and identifying tumor new antigens
CN110499324A
Treatment methods
WO2018175505A1
Nucleic acid NANO vaccine derived from bacterial outermembrane vesicle and use thereof
WO2023142999A1
